Nirsevimab, a monoclonal antibody targeting RSV, led to decreased hospitalizations for RSV-associated lower respiratory tract infection in infants during their first RSV season, in an open-label, pragmatic trial. Read the full HARMONIE trial results: nej.md/4au8JD5